1 published article · Updated continuously
11 trials tracked for Tardive Dyskinesia: 8 in phase 3 or 4 and 7 with published results. The most-cited published study has 335 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Valbenazine demonstrated a reduction in the Tardive Dyskinesia Impact Scale (TDIS) total score by 8.0 at week 24, alongside improvements in Sheehan Disability Scale scores and Euro Quality of Life Visual Analogue Scale scores 1.
MT-5199 showed statistically significant reductions in AIMS Total Scores at week 6 across both central and site assessments (p<0.001; p=0.013), with a notable percentage of patients achieving a ≥50% improvement from baseline 5.
NBI-98854 demonstrated statistically significant reductions in AIMS Dyskinesia Total Scores at week 6 in specific cohorts (p<0.0001) and showed improvements in Clinical Global Impression of Change - TD scores (p<0.0001) 11. However, other trials using NBI-98854 did not reach statistical significance for AIMS score changes at week 6 (p=0.2966) or CGI-TD improvements [9, 10].
SD-809 showed statistically significant reductions in centrally read AIMS scores at week 12 (p=0.0188) 8, while other trials using SD-809 reported mixed results regarding AIMS score changes at week 12 (p=0.001) 2 and did not reach statistical significance for mCDQ-24 scores 2. Long-term follow-up with SD-809 showed reductions in total motor AIMS scores at weeks 145 and 158 4.
AI synthesis of 6 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
